Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » New Target Identified for Scleroderma Therapy
Uncategorized

New Target Identified for Scleroderma Therapy

By medwebJun 22, 2010
Share
Facebook Twitter Email

New Target Identified for Scleroderma Therapy

Investigators at Northwestern University Feinberg School of Medicine have identified the molecule Egr-1 (early growth response factor 1) as a new therapy target for scleroderma, an autoimmune disease for which there currently is no cure.

Scleroderma, also known as systemic sclerosis, is a chronic autoimmune disease in which the body’s immune system turns on itself. It causes progressive thickening and tightening (fibrosis) of the skin and also can lead to serious internal organ damage and, in some cases, death. Scleroderma affects an estimated 300,000 people in the United States, most frequently young to middle-aged women.

“The implications of our discovery are broad-ranging because fibrosis, or scarring, underlies not only scleroderma, but also other more prevalent diseases such as pulmonary fibrosis, kidney fibrosis, liver cirrhosis, radiation-induced scars, and many others,” says John Varga, MD, professor of medicine-rheumatology and of dermatology at Feinberg and a physician at Northwestern Memorial Hospital. “The role of Egr-1 in fibrosis that we have identified is likely to apply to all of these conditions.”

The findings were spotlighted recently by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, along with similar research findings from the University of Pittsburgh School of Medicine. Both were published in the American Journal of Pathology.

Pharmacological agents used to treat type 2 diabetes mellitus, inflammation, and leukemia might block aberrant Egr-1 activity, Varga says, and could be useful as a novel treatment for scleroderma.

Varga directs the Northwestern Scleroderma Program, which is one of only a handful of centers in the nation that specialize in the disease. Since the disease affects multiple organs, optimal patient care requires the coordinated efforts of physicians from a wide variety of specialties to ensure comprehensive disease evaluation and management. Patients are also given the opportunity to participate in research studies, clinical trials, and education programs.

For the latest findings, Varga led a research team that included Northwestern scientists from pathology, plastic surgery, immunology, and pulmonary and critical care medicine. In one study, the team reproduced scleroderma in mice to show that the levels of the protein Egr-1 become highly elevated in the scar tissue. In a second study, the team used mice where the gene for Egr-1 was genetically deleted to demonstrate protection from the development of skin and lung fibrosis, in contrast to the genetically normal mice. Because the understanding of scleroderma and fibrosis represents a major unmet medical need, fresh insights into the disease process might open the door for novel therapies.

“The Northwestern research team continues to make fundamental contributions to scleroderma by focusing on its underlying molecular and cellular basis,” says Varga. “We believe that only by applying a careful mechanistic approach to dissect the role of cells, molecules, and pathways in this disease can we make real progress. We are now closer to treatments that could control the disease.”

Varga notes that interdisciplinary collaboration is necessary for discovery.

“Scleroderma is an unusually complex disease that simultaneously attacks the vascular, immune, and connective tissue systems and is affected by genetic factors,” he says. “In order to understand this disease, it is essential to explore each of these processes.”

The study was funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases and by the U.S. Department of Defense.

Share. Facebook Twitter Email

Related Posts

Mar 29, 2023

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

Lurie Cancer Center Receives Merit Extension from NCI

Oct 20, 2021

Drug Combination May Reduce Risk of Leukemia Relapse

Mar 26, 2020

Comments are closed.

Latest News

NUDOCS Program Inspires the Next Generation of Physicians

Mar 31, 2023

Women in Medicine Conference Celebrates Community

Mar 31, 2023

Self-Powered Wireless Implant Delivers Medication, Then Dissolves

Mar 30, 2023

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

The Future of IgE-Mediated Allergy Research and Treatments

Mar 29, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.